

**REMARKS**

Claims 1-3, 14, 16-29 and 31-32 are all the claims under consideration in the application. Claims 4-13, 15 and 30 have been cancelled. Attached are the amended claims labeled "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

A cross-reference to the parent application is added after the title. No new matter is added.

Applicants request prosecution of this application on the merits.

Respectfully submitted,



---


Heidi M. Berven  
Reg. No. 48,951  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-5218  
Fax (734) 622-1553

Attachment - Amended claims, Version with Markings to Show Changes Made

HB1P4099.doc

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Claim 1 (amended). A compound according to Formula I



or stereoisomers or pharmaceutically acceptable salts, esters, or amides [or prodrugs thereof], wherein:

A is selected from [N, Nalkyl,] NCH<sub>2</sub>, N(alkyl)CH<sub>2</sub>, CH<sub>2</sub>N, CH<sub>2</sub>N(alkyl) [, NO];

B is selected from H, (C<sub>3</sub>-20)alkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heteroalkylalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, each optionally substituted with R<sub>1</sub> and R<sub>2</sub>;

D is selected from H, (C<sub>3</sub>-20)alkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heteroalkylalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, each optionally substituted with R<sub>1</sub> and R<sub>2</sub>;

E is absent or selected from O, S, NH;

F is selected from N, NCH<sub>2</sub>, CH<sub>2</sub>N;

G is absent or selected from alkyl, alkyl interrupted by one or more heteroatoms, cycloalkyl, cycloalkyl interrupted by one or more heteroatoms;

J is absent or selected from aryl or heterocycle each optionally substituted with R<sub>1</sub> and R<sub>2</sub>;

403900-000-000

K is absent or selected from an alkyl, alkyl interrupted by one or more heteroatoms, cycloalkyl interrupted by one or more heteroatoms, cycloalkylalkyl interrupted by one or more heteroatoms, each optionally substituted with R<sub>1</sub> and R<sub>2</sub>;

L is selected from H, chlorine, fluorine, bromine, iodine, OH, O(alkyl), amine, alkyl, fluoroalkyl, amide, NO<sub>2</sub>, SH, S(O)<sub>n</sub>(alkyl), SO<sub>3</sub>H, SO<sub>3</sub>alkyl, aldehyde, ketone, acid, ester, urea, Oalkylamide, Oalkylester, Oalkylacid, Nalkylacid, alkylamine, alkylamide, alkylketone, alkylacid, alkylester, alkylurea, Nalkylamide, Nalkylester, NC(=O)alkyl, NC(=O)aryl, NC(=O)cycloalkyl, NC(=O)cycloalkylalkyl, NC(=O) alkylaryl, R<sub>1</sub>, R<sub>2</sub>, nitrile;

R<sub>1</sub> is selected from H, amine, alkylamine, amide, C(=NH)NHNH<sub>2</sub>, alkylC(=NH)NHNH<sub>2</sub>, C(=NH)NHOH, alkylC(=NH)NHOH, NHC(=NH)NH<sub>2</sub>, alkylNHC(=NH)NH<sub>2</sub>, C(=S)NH<sub>2</sub>, alkylC(=S)NH<sub>2</sub>, C(=NH)alkyl, alkylC(=NH)alkyl, C(=NR<sub>3</sub>)N(R<sub>4</sub>)(R<sub>5</sub>), alkylC(=NR<sub>3</sub>)N(R<sub>4</sub>)(R<sub>5</sub>);

R<sub>2</sub> is selected from H, chlorine, fluorine, bromine, iodine, OH, Oalkyl, amine, alkylaldehyde, alkylamide, alkylester, alkylketone, alkylacid, Oalkylamide, Oalkylacid, Oalkylester, aminealkylacid, aminealkylamide, aminealkylester, NC(=O)alkyl, NC(=O)aryl, NC(=O)cycloalkyl, NC(=O)alkylaryl, alkylamine, amide, aldehyde, ester, ketone, NO<sub>2</sub>, SH, S(O)<sub>n</sub>(C<sub>1-10</sub>alkyl), SO<sub>3</sub>H, SO<sub>3</sub>alkyl, CHO, acid, alkyl, C(=NH)alkyl, C(=NH)NHNH<sub>2</sub>, alkylC(=NH)NHNH<sub>2</sub>, C(=NH)NHOH, alkylC(=NH)NHOH, NHC(=NH)NH<sub>2</sub>, alkylNHC(=NH)NH<sub>2</sub>, C(=S)NH<sub>2</sub>, alkylC(=S)NH<sub>2</sub>, alkylC(=NH)alkyl, C(=NR<sub>3</sub>)N(R<sub>4</sub>)(R<sub>5</sub>), alkylC(=NR<sub>3</sub>)N(R<sub>4</sub>)(R<sub>5</sub>);

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are a hydrogen atom, alkyl group having 1 to 4 carbon atoms optionally interrupted by a heteroatom, or R<sub>4</sub> and R<sub>5</sub> are bonded to form -(CH<sub>2</sub>)<sub>p</sub>-W-(CH<sub>2</sub>)<sub>q</sub>, wherein p and q are an integer of 2 or 3, a certain position on the methylene chain is unsubstituted or substituted by an alkyl group having 1 to 4 carbon atoms, W is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>6</sub>)-, or -S(O)<sub>r</sub>- wherein R<sub>6</sub> is H or alkyl, and r is 0 or 1 or 2;

n is selected from 0, 1, 2;

X<sub>1</sub> is C or N;


X<sub>2</sub> is C or N;

X<sub>3</sub> is C or N;

X<sub>4</sub> is C or N; and

--- represents an optional additional bond when A is N.

Claim 3 (amended). A compound according to Claim 1 wherein the compound is according to Formula III



III

or stereoisomers or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof,

wherein A is [N or Nalkyl, and] B, G, J, K, L, and --- are as defined above.

Claim 14 (amended). A compound which is:

[7-Chloro-1-(3-dimethylamino-propyl)-3-phenyl-1H-quinoxalin-2-one;

7-Chloro-1-(3-dimethylamino-propyl)-3-phenyl-1H-quinoxalin-2-one;

3-(4-Chloro-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;

2(1H)-Quinoxalinone, 7-methoxy-1,3-bis(*p*-methoxyphenyl);

3-(3-Chloro-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;

3-(4-Fluoro-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;

3-(3,4-Dichloro-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;

1-(2-Diethylamino-ethyl)-4-oxy-3-phenyl-1H-quinoxalin-2-one;  
1-(2-Diethylamino-ethyl)-4-oxy-3-phenyl-1H-quinoxalin-2-one;  
3-(2-Chloro-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;  
3-(4-Bromo-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;  
2(1*H*)-Quinoxalinone, 7-methoxy-1-(*p*-methoxyphenyl)-3-phenyl;  
7-Methoxy-1-(4-methoxy-phenyl)-3-(4-trifluoromethyl-phenyl)-1H-quinoxalin-2-one;  
2(1*H*)-Quinoxalinone, 1-methyl-3-phenyl-, 4-oxide;  
7-Methoxy-1-(4-methoxy-phenyl)-3-(3-trifluoromethyl-phenyl)-1H-quinoxalin-2-one;]  
7-Methoxy-1-(4-methoxy-phenyl)-3-p-tolyl-1H-quinoxalin-2-one[;  
3-(2-Fluoro-phenyl)-7-methoxy-1-(4-methoxy-phenyl)-1H-quinoxalin-2-one;  
1-(3-Diethylamino-propyl)-3-phenyl-1H-quinoxalin-2-one;  
7-Hydroxy-1-(4-hydroxy-phenyl)-3-phenyl-1H-quinoxalin-2-one;  
3-(4-Chloro-phenyl)-1-phenyl-1H-quinoxalin-2-one;  
2(1*H*)-Quinoxalinone, 1,3-diphenyl;  
1-[5-(2,6-Dimethyl-piperidin-1-yl)-penty]-3-phenyl-1H-quinoxalin-2-one;  
3-{4-[5-(2,6-Dimethyl-piperidin-1-yl)-penty]-1-methyl-3-oxo-1,2,3,4-tetrahydro-  
quinoxalin-2-yl}-N-hydroxy-benzamide;  
3-{4-[5-(2,6-Dimethyl-piperidin-1-yl)-penty]-3-oxo-3,4-dihydro-quinoxalin-2-yl}-N-  
hydroxy-benzamide;  
3-(3-Amino-1*H*-indazol-5-yl)-1-[5-(2,6-dimethyl-piperidin-1-yl)-penty]-1*H*-  
quinoxalin-2-one; or  
2(1*H*)-Quinoxalinone, 1-[2-(diethylamino)ethyl]-3-[[4-(methoxy)phenyl]methyl]].

2025 RELEASE UNDER E.O. 14176